AI Strategy · Pharma & Healthcare

AI strategy that respects the evidence bar you already work to.

I help pharmaceutical and healthcare organisations adopt AI responsibly. Twelve years inside the industry means I start from your regulatory, HTA and clinical constraints — not around them.

Ryan Bishop
Surrey, UK · BCS Member

How I can help

I work in a few ways depending on what an organisation actually needs. Every engagement starts from your constraints and the evidence you have to meet.

Engagements are shaped around the problem — not packaged.
01

Strategic advisory

Project-based or ongoing advisory on where AI genuinely adds value in HEOR, market access, pricing and value communication — and where it does not. Grounded in regulatory, HTA and clinical realities.

HEORMarket accessHTAGovernance
02

Speaking & workshops

Sessions for teams and leadership on responsible AI, governance, and AI literacy — pitched for regulated environments, not generic tech audiences.

LeadershipTeamsGovernanceLiteracy
03

Collaboration

Initiatives that need both pharmaceutical domain expertise and AI capability in one place — from evidence frameworks to internal reference tools.

EvidenceToolingOnboarding
For pharma & healthcare organisations

AI strategy that respects your evidence bar.

Regulatory requirements, HTA frameworks, payer realities, clinical governance — none of this fits a generic template. Twelve years inside the industry means I start from your constraints, not around them.

See how I can help →
For families & teams

AI literacy without fear or fluff.

As a father of three, I care about people using AI thoughtfully. A free weekly brief, plain-language explainers, and talks.

Explore AI Literacy →
The AI Brief

Current AI news meets peer-reviewed research — every week.

One short email for pharma, market access and HEOR. Themed news with a plain-English "so what?", plus recent papers with lay summaries. Free PDF.

Free · weekly · unsubscribe any time · via EmailOctopus
The AI Brief №8 · 26 May
This week, in healthcare AI:
◆ NIHR i4i £10m call closes — the RWE route to full NICE guidance
◆ EU AI Act transparency consultation closes 3 June
◆ EU AI Act high-risk deadlines confirmed — Dec 2027 / Aug 2028
The background behind the advice
12 years
Pharmaceutical consulting — HEOR, pricing, market access, value communication
Published
Cancer research, Institute of Cancer Research
MA in progress
AI & Digital Transformation, University of Southampton
BCS Member
The Chartered Institute for IT
"The most important AI challenges in healthcare aren't technical — they're strategic, organisational, and human."